Form 4: Olema Director Sells Shares Under 10b5-1 Plan

Olema Pharmaceuticals Director Cyrus Harmon sold 3,489 shares of common stock at an average price of $29.12 under a pre-arranged 10b5-1 plan.

Summary

• Cyrus Harmon, a Director of Olema Pharmaceuticals, Inc. (OLMA), reported a sale of common stock.
• The transaction involved the disposition of 3,489 shares of common stock.
• The shares were sold on January 14, 2026, at a weighted average price of $29.12 per share.
• The sale price range was between $29.00 and $29.23.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale.
• Following the transaction, Harmon directly owns 737,770 shares and indirectly owns 117,028 shares through Harmon Family Investors LLC.

Sentiment

Score: 5

Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 plan, which is a neutral event in terms of company sentiment. It does not reflect new information about the company's operational performance or future prospects.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, which indicates a pre-scheduled sale not based on new, non-public information, enhancing transparency and mitigating concerns about opportunistic insider trading.

Negatives

• A director selling shares, even under a 10b5-1 plan, could be perceived negatively by some investors as it represents a reduction in insider ownership.

Future Outlook

This Form 4 filing is a report of a past transaction and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

Insider sales, particularly those executed under a Rule 10b5-1 plan, are common in the biotechnology and pharmaceutical industry as executives manage personal finances and diversify holdings. This specific transaction by a director of Olema Pharmaceuticals is a routine disclosure of a pre-scheduled stock sale, aligning with typical insider activity observed across the sector.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting an insider transaction. The use of a 10b5-1 plan aligns with best practices for corporate insiders to sell shares without concerns of trading on material non-public information, a common practice across publicly traded companies, including peers like Moderna (MRNA) or BioNTech (BNTX) where executives also utilize such plans for share dispositions.

Related Party Transactions

• The indirect ownership of 117,028 shares by Harmon Family Investors LLC, of which the Reporting Person is the manager, could be considered a related party holding, though the reported transaction itself is a direct sale by the reporting person.

Stakeholder Impact

• Shareholders: May observe a director selling shares, but the 10b5-1 plan mitigates concerns about trading on non-public information, suggesting the sale is for personal financial management rather than a reflection of company-specific issues.

Key Dates

Recommendation

This Form 4 filing details a routine insider sale by a director under a pre-arranged 10b5-1 plan. Such transactions are typically for personal financial management and do not inherently signal a change in the company's fundamental outlook or performance. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Olema Pharmaceuticals, OLMA, Cyrus Harmon, Insider Trading, Form 4, Stock Sale, Director, 10b5-1 Plan